B alloon angioplasty and stent implantation are widely used techniques to treat patients with obstructive atherosclerosis. As a major limitation, such procedures are associated with a 25% to 40% risk of lumen renarrowing during the first 6 months after intervention. 1 This process, also called restenosis, is caused by intervention-associated vascular injury and mediated by inward arterial remodeling and the formation of neointimal lesions consisting mainly of smooth muscle cells (SMCs) and inflammatory leukocytes. 2,3 A fraction of the neointimal SMCs driving injury-induced neointimal hyperplasia has been shown to originate from bone marrow-derived or circulating smooth muscle progenitor cells in a Cxcl12/ Cxcr4-dependent way. [4] [5] [6] [7] The chemokine receptor Cxcr4 and its ligand Cxcl12, also called stromal cell-derived factor-1, play an important role in the homing of progenitor cells in the bone marrow and in their mobilization to the periphery Objective-The Cxcl12/Cxcr4 chemokine ligand/receptor axis mediates the mobilization of smooth muscle cell progenitors, driving injury-induced neointimal hyperplasia. This study aimed to investigate the role of endothelial Cxcr4 in neointima formation. Approach and Results-β-Galactosidase staining using bone marrow x kinase (Bmx)-CreER T2 reporter mice and double immunofluorescence revealed an efficient and endothelial-specific deletion of Cxcr4 in Bmx-CreER T2+ compared with Bmx-CreER T2− Cxcr4-floxed apolipoprotein E-deficient (Apoe − / − ) mice (referred to as Cxcr4 EC-KO ApoE −/− and Cxcr4 EC-WT ApoE −/− , respectively). Endothelial Cxcr4 deficiency significantly increased wire injury-induced neointima formation in carotid arteries from Cxcr4 EC-KO ApoE −/− mice. The lesions displayed a higher number of macrophages, whereas the smooth muscle cell and collagen content were reduced. This was associated with a significant reduction in reendothelialization and endothelial cell proliferation in injured Cxcr4 EC-KO ApoE −/− carotids compared with Cxcr4 EC-WT ApoE −/− controls. Furthermore, stimulation of human aortic endothelial cells with chemokine (C-X-C motif) ligand 12 (CXCL12) significantly enhanced their wound-healing capacity in an in vitro scratch assay, an effect that could be reversed with the CXCR4 antagonist AMD3100. Also, flow cytometric analysis showed a reduced mobilization of Sca1 + Flk1 + Cd31 + and of Lin − Sca1 + progenitors in Cxcr4 EC-KO ApoE −/− mice after vascular injury, although Cxcr4 surface expression was unaltered. No differences could be detected in plasma concentrations of Cxcl12, vascular endothelial growth factor, sphingosine 1-phosphate, or Flt3 (fms-related tyrosine kinase 3) ligand, all cytokines with an established role in progenitor cell mobilization. Nonetheless, double immunofluorescence revealed a significant reduction in local endothelial Cxcl12 staining in injured carotids from Cxcr4 EC-KO ApoE −/− mice.
under pathological conditions. 8 In line with this, either deficiency or blocking of the Cxcl12/Cxcr4 axis reduced smooth muscle progenitor cell recruitment and neointima formation after vascular injury. 5, 7, 9 Of note, these studies induced a global blockade of Cxcl12/Cxcr4 signaling through the use of Cxcr4 antagonists, 7, 9 Cxcl12 blocking antibodies, 5, 7 or bone marrow transplantation with Cxcr4-deficient cells. 7 Thus, cell type-specific effects of Cxcr4 on injury-induced neointimal hyperplasia remain unknown. Especially, the role of Cxcr4 in vascular endothelial cells (ECs) is an intriguing open question, because an efficient reendothelialization of a denudated vessel is important in slowing down restenosis and preventing thrombosis. 10 Endothelial seeding or implants on the injured vascular wall have been proven to enhance endothelial recovery and significantly reduce neointimal hyperplasia. 11, 12 Although antiproliferative agents of drug-eluting stents can reduce neointimal inflammation and SMC proliferation, they also enhance the risk of late stent thrombosis attributable to an impairment in EC proliferation and vascular reendothelialization. 13, 14 In this study, we investigated the effect of an endothelial-specific Cxcr4 deletion on neointimal hyperplasia after carotid artery injury using bone marrow x kinase (Bmx)-CreER T2 Cxcr4-floxed apolipoprotein E-deficient (Apoe −/− ) mice, in which conditional deletion of endothelial Cxcr4 was induced by tamoxifen treatment. We hypothesized that endothelial Cxcr4 deficiency may enhance neointima formation through an impaired reendothelialization of the denudated artery.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Mouse Model
Five-to 7-week-old female Bmx-CreER T2 + Cxcr4-floxed Apoe −/− mice (indicated as Cxcr4 EC-KO Apoe −/− ) and littermate Bmx-CreER T2 -Cxcr4floxed Apoe −/− controls (indicated as Cxcr4 EC-WT Apoe −/− ) were treated with tamoxifen to induce Cre-mediated deletion of the floxed Cxcr4 allele in Bmx + cells. After a recovery period of minimal 3 weeks after the first tamoxifen injection and 1 week of high-fat diet, wire-mediated injury of the left common carotid artery was induced as previously described. 5 Animal experiments were reviewed and approved by local authorities in accordance with the German animal protection law.
Neointimal Lesion Analysis
Serial 4-μm transversal sections of injured carotid arteries were stained with the Elastica-van Gieson staining, Sirius Red, or with specific antibodies and isotype controls, as indicated.
Flow Cytometry
Circulating Sca1 + Flk1 + Cd31 + mononuclear progenitor cells [15] [16] [17] [18] and Lin − Sca1 + progenitor cells were quantified after labeling of peripheral blood cells with directly conjugated antibodies.
In Vitro Scratch Assay
Human aortic ECs (HAoECs) were grown to confluency and stimulated with the indicated compounds for 8 hours before and 20 hours after wound introduction.
Results

Efficient Deletion of Endothelial Cxcr4 in Carotid Arteries by Using the Bmx-CreER T2 Transgene
Bmx was previously reported to be highly expressed in the endocardium and in arterial ECs, but not in venous endothelium. 19, 20 Analysis of β-galactosidase activity in Bmx-CreER T2 ROSA reporter mice revealed a specific and intense blue staining in the endothelial cell layer of the carotid artery ( Figure 1A ), confirming the suitability of the Bmx-CreER T2 transgenic mouse line to induce a conditional gene deficiency in the endothelium of carotid arteries. Furthermore, double immunostaining of carotid artery sections for Cxcr4 and the EC marker Cd31 displayed Cxcr4 expression in only 26% of the endothelium in Cxcr4 EC-KO Apoe −/− compared with 70% in Cxcr4 EC-WT Apoe −/− controls ( Figure 1B 
Endothelial Cxcr4 Deficiency Enhances Neointimal Hyperplasia After Vascular Injury
Plasma cholesterol and triglyceride levels were similar in Cxcr4 EC-KO Apoe −/− and Cxcr4 EC-WT Apoe −/− mice ( Figure II in the online-only Data Supplement). No significant differences were observed in the number of circulating platelets, leukocytes, and leukocyte subsets, including monocytes, lymphocytes, and neutrophils. Furthermore, the relative frequencies of Gr1 high versus Gr1 low monocyte subsets, of T cells and its CD4 versus CD8 subgroups, and of B lymphocytes were not significantly changed, as determined by flow cytometric analysis (Figures III and IV in the online-only Data Supplement). However, endothelial Cxcr4 deficiency induced a significant increase in neointima formation 4 weeks after vascular injury ( Figure 2A ; Figure VA in the onlineonly Data Supplement). No significant effects were observed on luminal area, medial area, or the area within the external elastic lamina before or after injury (Figure 2B-2D; Figure VB in the online-only Data Supplement). The smooth muscle actin + SMC content of neointimal lesions was significantly reduced in Cxcr4 EC-KO Apoe −/− mice, which corresponded with a significant decrease in collagen-rich extracellular matrix ( Figure 3A and 3B). Conversely, a significant increase was observed in Mac2 + lesional macrophages ( Figure 3C ). Identification of neointimal macrophages with Mac2 correlated well with alternative usage of the macrophage marker F4/80, as determined by both immunostaining and flow cytometry ( Figure VI in the online-only Data Supplement). Local macrophage proliferation in neointimal lesions was not significantly altered ( Figure 3D ). Thus, endothelial Cxcr4 deficiency triggered the formation of larger injuryinduced neointimal lesions with a more inflammatory phenotype.
Endothelial Cxcr4 Is Important for Efficient Reendothelialization of Denudated Arteries
Because reendothelialization is a crucial step in limiting injuryinduced neointimal hyperplasia, 10 of endothelial Cxcr4 deficiency on the endothelial recovery process after endothelial denudation of the carotid arteries.
Immunostaining for Cd31 revealed that the degree of reendothelialization reached only 49% in the Cxcr4 EC-KO Apoe −/− mice 3 weeks after vascular injury, which was significantly lower than the 64% reendothelialization efficiency in the Cxcr4 EC-WT Apoe −/− controls ( Figure 4A ). The role of CXCR4 in the wound-healing capacity of ECs was further investigated in a scratch migration assay in vitro using HAoECs, which express CXCR4 and respond to the CXCR4 ligand CXCL12 as shown by a decreased CXCR4 surface expression in response to CXCL12 stimulation ( Figure VII in the online-only Data Supplement). Interestingly, stimulation of HAoECs with CXCL12 significantly enhanced their migration into the scratched area, which could be reversed with the CXCR4 antagonist AMD3100 ( Figure 4B ). CXCL12 could not enhance basal proliferation of HAoECs in vitro ( Figure 4C ). Nevertheless, staining of carotid artery sections for Cd31 in combination with the proliferation marker Ki67 revealed a significant reduction in proliferating ECs in injured carotid arteries from Cxcr4 EC-KO Apoe −/− mice compared with those from Cxcr4 EC-WT Apoe −/− controls ( Figure 4D ). Together, these results demonstrate that the chemokine receptor Cxcr4 plays an important role in the migration and proliferation response of ECs after vascular denudation in vivo.
Endothelial Cxcr4 Deficiency Reduces the Mobilization of Sca1 + Flk1 + Cd31 + Cells
Previous studies have shown that endothelial progenitor cells (EPCs) contribute to an efficient reendothelialization of denudated vessels. 21 Although there are no unique markers for defining EPCs, Sca1 + Flk1 + expression is regularly being used for flow cytometric analysis of circulating EPCs in mice. [15] [16] [17] [18] Mouse Sca1 + Flk1 + mononuclear cells were also Cd31 + and showed an forward scatter/side scatter pattern distinct from typical monocytes ( Figure 5A ). Furthermore, Cd45 + mononuclear leukocytes infiltrated into neointimal lesions of carotid arteries 3 weeks after injury were mainly Flk1 − , and also Cd45 − vascular cells were Flk1 − . In contrast, F4/80 + neointimal macrophages were found to be Flk1 + ( Figure VIIIA in the online-only Data Supplement), corresponding with an earlier report of Flk1 expression on non-SMCs in injury-induced neointimal lesions in carotid arteries from rat and rabbit. 22 Flk1 expression on lesional macrophages could also be detected by coimmunostaining of injury-induced neointimal lesions for Flk1 and the macrophage marker Mac2, however with variable efficiency probably attributable to the low immunofluorescent Flk1 signal revealed by immunostaining ( Figure VIIIB in the online-only Data Supplement). Furthermore, Flk1 expression on macrophages seems context dependent because only a small percentage of thioglycollate-elicited peritoneal macrophages was found to be Flk1 + by flow cytometric analysis ( Figure VIIIC in the online-only Data Supplement).
Quantification of circulating Sca1 + Flk1 + Cd31 + cells did not reveal differences between Cxcr4 EC-WT Apoe −/− and Cxcr4 EC-KO Apoe −/− mice at baseline conditions ( Figure 5B ). Vascular injury significantly increased the level of circulating Sca1 + Flk1 + Cd31 + cells in Cxcr4 EC-WT Apoe −/− but not Cxcr4 EC-KO Apoe −/− mice ( Figure 5B ). Comparably, Cxcr4 EC-KO Apoe −/− mice showed a significantly reduced mobilization of circulating Lin − Sca1 + progenitor cells after injury ( Figure 6A and 6B). No significant differences were observed in the number of Sca1 + Flk1 + Cd31 + or Lin − Sca1 + progenitor cells in the bone marrow before or after injury ( Figure IX in the onlineonly Data Supplement). Because the Cxcl12/Cxcr4 axis plays an important role in the mobilization of progenitor cells from the bone marrow to the periphery, 8 and the Cxcr4 receptor has also been implicated in mediating progenitor cell recruitment to injured carotid arteries, 7, 23 we questioned whether the reduced mobilization of Sca1 + Flk1 + Cd31 + progenitors in the Cxcr4 EC-KO Apoe −/− mice could be related to a potential deletion of Cxcr4 in these cells mediated by the Bmx-Cre transgene. Analysis of Cxcr4 expression on the surface of circulating Sca1 + Flk1 + Cd31 + cells by flow cytometry showed them to be clearly Cxcr4 positive, without significant differences in the Cxcr4 expression level, represented by the geometric mean fluorescence intensity between Cxcr4 EC-WT Apoe −/− and Cxcr4 EC-KO Apoe −/− mice ( Figure XA in the online-only Data Supplement). Thus, these data indicate that the reduced level of circulating Sca1 + Flk1 + Cd31 + cells in injured Cxcr4 EC-KO Apoe −/− is not caused by a Cxcr4 deficiency in these progenitors themselves. Comparably, no statistically significant differences were found in the Cxcr4 level on circulating Lin − Sca1 + progenitor cells ( Figure XB in the online-only Data Supplement).
To explore potential mechanisms underlying the observed effects on progenitor cell mobilization, we quantified plasma concentrations of different stimuli known to be involved in this process. Cxcl12 is an important ligand for Cxcr4, and ECs were previously shown to produce Cxcl12 through a Cxcl12/ Cxcr4-positive feedback loop. 24 However, no differences were observed in the Cxcl12 level in plasma or bone marrow from Cxcr4 EC-WT Apoe −/− and Cxcr4 EC-KO Apoe −/− mice after vascular injury ( Figure 7A ). Plasma concentrations of Vegf, Flt3 ligand, and the sphingolipid sphingosine 1-phosphate, which can all influence progenitor cell mobilization, were unaltered at different time points after injury ( Figure 7B -7D), whereas plasma levels of granulocyte-macrophage colony stimulating factor (GM-CSF) remained below detection levels. Similarly, plasma concentrations of macrophage migration inhibitory factor (Mif), an alternative ligand of Cxcr4 able to mediate EPC chemotaxis in vitro through Cxcr4, 25 were unchanged until 10 days after injury. Surprisingly, Cxcr4 EC-KO Apoe −/− mice showed a significant increase in Mif plasma levels at later stage ( Figure 7E ), which can thus also not explain the decreased mobilization of Sca1 + Flk1 + Cd31 + progenitors. However, immunostaining of injured carotid artery sections for Cxcl12 and Cd31 revealed a significantly lower Cxcl12 level in the vascular endothelium of Cxcr4 EC-KO Apoe −/− mice after injury ( Figure 7F ).
Together, our results demonstrate a reduced injury-induced mobilization of Sca1 + Flk1 + Cd31 + progenitor cells on endothelial Cxcr4 deficiency, which may contribute to the observed reduction in reendothelialization. Although the underlying mechanisms of decreased mobilization remain currently unclear, it is possible that reduced immobilization of adluminal Cxcl12 on injured vascular endothelium of Cxcr4 EC-KO Apoe −/− mice may contribute indirectly to reduced progenitor cell mobilization.
Discussion
In this study, we showed that deficiency of endothelial Cxcr4 significantly interfered with the recovery of injured endothelium and enhanced neointima formation in a mouse model of carotid artery injury. Reduced reendothelialization of injured carotid arteries from Cxcr4 EC-KO Apoe −/− mice was associated with a decreased endothelial proliferation in vivo, a reduced migratory wound-healing capacity of vascular ECs in vitro, as well as with a lower mobilization of circulating Sca1 + Flk1 + Cd31 + progenitors after injury.
Efficient reendothelialization of a denudated vessel has been shown to be important in slowing down neointimal hyperplasia. For example, overexpression of endostatin, a selective inhibitor of EC proliferation, significantly reduced endothelial recovery after endothelial denudation of the mouse femoral artery; and 4 weeks after injury, the degree of reendothelialization showed a significant inverse correlation with neointima formation. 26 Comparably, sequestration of the potent EC mitogen Vegf significantly reduced endothelial proliferation and reendothelialization, and enhanced neointimal hyperplasia after endothelial denudation, whereas opposite results were obtained with Vegf overexpression or local treatment. 27, 28 Also, endothelial seeding or implants on the injured vascular wall or local treatment with culture-modified mononuclear cells displaying an endothelium-like phenotype have been proven to enhance endothelial recovery and significantly reduce neointimal hyperplasia in a rabbit and pig injury model. 11, 12, 29 These data, together with our observation that enhanced neointima formation in the absence of endothelial Cxcr4 is associated with a reduced reendothelialization level, underscore the notion that vascular endothelium and injury-induced endothelial repair are key modulators of neointimal hyperplasia after arterial injury.
Migration and proliferation of ECs from adjacent noninjured endothelium are important factors driving vascular reendothelialization. Blocking the CXCR4 receptor with the antagonist AMD3100 significantly reduced the CXCL12-triggered wound-healing capacity of ECs in an in vitro scratch migration assay ( Figure 4B ). The relatively small, yet significant, effect of CXCL12 stimulation on the EC regeneration ability could be related to the heterogeneous expression level of CXCR4 on HAoEC, with >60% of cultured ECs presenting only a relatively small level of surface CXCR4 ( Figure VII in the onlineonly Data Supplement). Furthermore, deficiency of endothelial Cxcr4 resulted in a significant reduction of endothelial proliferation at the site of injury ( Figure 4D ). Because CXCL12 could not directly enhance proliferation of human ECs in vitro, we speculate that effects of endothelial Cxcr4 deficiency on EC proliferation in injured vessels are controlled by additional factors released from the site of injury. Alternatively, it is possible that MIF, an alternative ligand for CXCR4, influences EC proliferation after injury through CXCR4, either by direct interaction or by binding its receptor CXCR2 in heterodimerization with CXCR4, for example, through joint interaction with CD74. 30 Such mitogenic effect of recombinant MIF on human coronary artery ECs was previously shown in vitro, although receptor involvement was not examined. 31 In addition to stimulating reendothelialization through migration and proliferation of vascular ECs, recruitment of EPCs to the injured site has been associated with efficient reendothelialization of denudated arteries, and transplantation or mobilization of EPCs has been linked with enhanced vascular repair after injury. 21 For example, systemic injection or local treatment of injured arteries with purified EPCs significantly enhanced reendothelialization and reduced neointimal thickening in mouse or rabbit injury models. 17, [32] [33] [34] These beneficial effects were further enlarged when the EPCs were pretreated with the protein kinase GSK3-β (glycogen synthase kinase 3 beta), which improved the adhesion capacity of the injected EPCs. 34 Furthermore, cilostazol treatment of rats significantly reduced neointimal hyperplasia after balloon carotid denudation, which was associated with an enhanced reendothelialization in vivo and an increased mobilization, proliferation, and differentiation capacity of EPCs in vitro. 35 Also, enhanced mobilization of mononuclear cells expressing endothelial cell lineage markers (eg, Flk1) on treatment with G-CSF (granulocyte colony stimulating factor) 36, 37 or GM-CSF 38 was linked with an improved endothelial repair and reduced neointima formation after vascular injury in rat, mouse, and rabbit. In conclusion, increased levels of circulating EPCs have been associated with a higher reendothelialization degree of denudated vessels.
Similar results were obtained in our study, in which a lower endothelial recovery was observed in injured Cxcr4 EC-KO Apoe −/− mice displaying a significantly lower level of circulating Sca1 + Flk1 + Cd31 + progenitors compared with Cxcr4 EC-WT Apoe −/− controls ( Figure 5 ). Circulating EPCs are poorly defined, and their definition is currently intensely debated. 18 Gating of Sca1 + Flk1 + cells, which we found to be also Cd31 + , has recurrently been used in mice to quantify such circulating EPCs. [15] [16] [17] Furthermore, induced pluripotent stem cell-derived Flk1 + cells were recently shown to prevent injury-induced neointimal thickening in mice through enhanced reendothelialization, 39 supporting a role for Flk1 + progenitor cells in injury-induced endothelial repair. However, whether EPCs contribute to endothelial repair through differentiation into ECs and integration in the injured endothelium, or rather through paracrine effects on resident ECs through secretion of stimulatory molecules, is still heavily debated. 40 Cxcr4 is an important chemokine receptor regulating the mobilization of EPCs and other progenitor cells to peripheral sites of injury through injury-induced upregulation of Cxcl12. 41 In the context of carotid artery injury in mice, antibody-mediated blocking of Cxcr4 on EPCs significantly reduced their adhesion rate to injured arteries ex vivo and in vivo 17, 23 and abolished the capacity of infused EPCs to promote endothelial recovery and reduce neointimal hyperplasia after vascular injury. 17, 42 In contrast, overexpression of Cxcr4 enhanced the adhesion and Cxcl12-induced migration ability of EPCs in vitro and significantly increased the capacity of EPCs to promote injury-induced reendothelialization. 43 However, Cxcr4 EC-KO Apoe −/− mice did not show a reduced Cxcr4 expression on circulating Sca1 + Flk1 + Cd31 + cells ( Figure  X in the online-only Data Supplement). This indicates that Bmx is not expressed on their precursor cells at the time of tamoxifen treatment, and that differences in the attracting chemokine concentration instead of altered chemokine receptor levels on Sca1 + Flk1 + Cd31 + progenitors underlie their reduced levels in peripheral blood. Although the concentration of Cxcl12 in plasma and bone marrow was not changed after injury ( Figure 7A ), endothelial Cxcl12 levels at the injured site were significantly reduced in Cxcr4 EC-KO Apoe −/− mice compared with Cxcr4 EC-WT Apoe −/− controls ( Figure 7F ). This may reflect a reduced immobilization of Cxcl12 on Cxcr4-deficient endothelium or could be related to a decreased endothelial Cxcl12 expression, given that Cxcl12 and endothelial apoptotic bodies generated after endothelial injury trigger endothelial Cxcl12 expression through a Cxcr4-mediated positive feedback loop. 24 The decreased endothelial Cxcl12 staining suggests that a local reduction in luminally exposed Cxcl12 on the endothelium of injured arteries from Cxcr4 EC-KO Apoe −/− mice may contribute to reduced reendothelialization through a reduction in adhesion or mobilization of endothelial cell progenitors. 17, 23, 44 This is further supported by recent findings that Cxcl12 can indeed mediate EPC migration, adhesion, and survival, 17, [41] [42] [43] [44] and that treatment of mice with a Cxcl12 blocking antibody significantly reduces circulating Sca1 + Flk1 + EPC numbers and reendothelialization after carotid artery injury. 17 Furthermore, the importance of locally increased Cxcl12 availability in the recruitment of bone marrow-derived cells to sites of injury has previously been shown in different injury models. 41, 44, 45 Also, a previous report demonstrated an association between (endothelial) progenitor cells adhering to the luminal side of atherosclerotic vessels and Reduced chemokine (C-X-C motif) ligand 12 (Cxcl12) levels in injured chemokine (C-X-C motif) receptor 4 (Cxcr4)-deficient endothelium. A, Cxcl12 concentration in plasma (left) or bone marrow (right) before or after injury, as indicated; n=5 to 6 (for bone marrow) or n=8 to 13 (for plasma). B-E, Plasma concentrations of vascular endothelial growth factor (Vegf), fms-related tyrosine kinase 3 (Flt3) ligand, sphingosine-1-phosphate (S1P), and macrophage migration inhibitory factor (Mif), before or after injury, as indicated. Measurements of heparin-plasma are presented in separate graphs (D and E, left) as EDTA-plasma (all other images), as heparin-vs EDTA-plasma can differentially affect absolute ELISA readouts. n=2 to 4 (for Mif baseline and 1 day) or n=5 to 8 (for all others). F, Quantification of endothelial Cxcl12 levels in carotid arteries from Cxcr4 EC-WT Apoe −/− and Cxcr4 EC-KO Apoe −/− mice 3 weeks after injury, based on staining of carotid artery sections for Cd31 (red), Cxcl12 (green), and DAPI (blue). The graph displays the Cxcl12 + Cd31 + luminal length as percentage of the total Cd31 + luminal length; n=8 to 13. Representative images are shown. Cxcl12 + Cd31 + cells (yellow) are indicated with arrows. Scale bars, 50 μm. A-F, Graphs represent means±SEM; **P<0.01 and ***P<0.001; 2-way ANOVA with Bonferroni post-test (E) or 2-tailed t test (F), as appropriate.
enhanced luminal Cxcl12 expression after treatment of mice with endothelial apoptotic bodies. 24 Together, these data support a role for luminally exposed Cxcl12 on the endothelium in the recruitment of Sca1 + Flk1 + Cd31 + progenitors to injured vessels.
Which molecular mechanisms underlie the decreased mobilization of Sca1 + Flk1 + Cd31 + cells in the blood of injured Cxcr4 EC-KO Apoe −/− mice remains currently unclear. Of note, the apparent absence of differences in plasma and bone marrow Cxcl12 levels could be related to the specificity of the ELISA-based measurement for the Cxcl12-α isoform, whereas differences in local endothelial Cxcl12 levels were revealed with an antibody recognizing both the αand β-isoform. Therefore, it could be hypothesized that reduced progenitor cell mobilization in Cxcr4 EC-KO Apoe −/− mice is caused by reduced plasma levels of Cxcl12-β or even another Cxcl12 isoform. Such isoform-specific role of Cxcl12 has previously been suggested in the context of cerebral ischemia, where leukocyte infiltration was associated with endothelial Cxcl12-β but not -α. 46 Furthermore, it is conceivable that endothelial Cxcr4 deficiency modifies progenitor cell recruitment in stress conditions by directly or indirectly affecting local or systemic levels of mobilizing factors, other than Cxcl12. For example, Cxcl12/Cxcr4 signaling can induce production of Vegf 47, 48 and the sphingolipid sphingosine 1-phosphate through mechanistic target of rapamycin. 49, 50 Both mediators are produced in ECs and can mediate progenitor cell mobilization. 8, 50 However, we could not detect differences in plasma levels of Vegf or sphingosine 1-phosphate after injury of Cxcr4 EC-WT Apoe −/− versus Cxcr4 EC-KO Apoe −/− mice, and plasma concentrations of Flt3 ligand, with a known role in progenitor cell mobilization, remained unchanged. Surprisingly, Mif, an alternative Cxcr4 ligand able to mediate EPC chemotaxis through Cxcr4 in vitro, 25 showed unaltered plasma levels up to 10 days after injury but was significantly increased in plasma of injured Cxcr4 EC-KO Apoe −/− mice at later stage. Because Mif was shown to be mostly expressed by neointimal foam cells at 2 weeks after injury, compared with a mainly SMC-dependent expression of Mif 1 day after injury, 51 it can be hypothesized that the increased macrophage content of neointimal lesions in injured Cxcr4 EC-KO Apoe −/− mice contributes to the observed increase in plasma Mif levels at later stage. It is possible that endothelial Cxcr4 deficiency affects plasma levels of other signaling molecules mediating progenitor cell mobilization from the bone marrow in conditions of stress, as, for example, endothelial NO synthase, angiopoietin-1, or the chemokines Il-8 and Gro-β, among others. 8 Alternatively, a decrease in Cxcl12-dependent recruitment and survival of progenitor cells at the injured site could cause a reduced secretion of such mobilization factors from the recruited cells, as observed after skin wounding. 52 In addition, a different inflammatory context in the neointima could contribute to the observed reduction in progenitor cell mobilization in Cxcr4 EC-KO Apoe −/− mice through a modified expression of mobilizing proteins. Future studies, using mice with an endothelial-specific Cxcl12 deficiency, are required to investigate the role of endothelial Cxcl12 expression in the injury-induced mobilization and recruitment of Sca1 + Flk1 + Cd31 + progenitors in more detail.
Although long-term treatments with Cxcr4 antagonists have been shown to stimulate EPC mobilization in mice, 53 these antagonists also interfered with the adhesion, migration, and proliferation capacity of EPCs in vitro. 54 This can explain why systemic treatment of mice with Cxcr4 antagonists did not affect the reendothelialization degree after carotid artery injury in mice, 9, 55, 56 in contrast to BmxCreER T2 -mediated EC-specific Cxcr4 deficiency studied in this article.
Furthermore, the observed decrease in injury-induced neointima formation in mice treated with Cxcr4 antagonists was associated with a reduced mobilization of Lin − Sca1 + progenitor cells in the peripheral blood, 9, 56 a phenomenon that was also observed on treatment of mice with a Cxcl12 blocking antibody. 7 Similarly, Cxcr4 EC-KO Apoe −/− mice displayed a lower injury-induced mobilization of Lin − Sca1 + cells (Figure 7) . This was not associated with a decreased surface expression of Cxcr4, again suggesting that the reduced endothelial Cxcl12 expression in Cxcr4 EC-KO Apoe −/− mice at the site of injury is directly or indirectly involved in the reduced mobilization of Lin − Sca1 + progenitor cells. Lin − Sca1 + progenitors recruited through the Cxcl12/Cxcr4 axis have been shown to contribute to injury-induced neointimal hyperplasia through differentiation in neointima-driving SMCs at the site of injury. 5, 7 Thus, the reduced Lin − Sca1 + mobilization in the Cxcr4 EC-KO Apoe −/− mice may underlie the reduced number of neointimal SMCs (Figure 3A) , providing a protective effect on itself. However, the overall increase in neointima formation in these mice indicates that this protective effect is surmounted by the reduced reendothelialization efficiency in injured Cxcr4 EC-KO Apoe −/− mice, which allows for a higher infiltration of inflammatory macrophages ( Figure 3C ), shown to contribute to injury-induced neointimal hyperplasia. 57, 58 In summary, this study reveals an important protective role of endothelial Cxcr4 and the Cxcl12/Cxcr4 axis in injury-induced neointima formation by promoting efficient reendothelialization, mediated by endothelial migration and proliferation in vivo, as well as by mobilization of protective Sca1 + Flk1 + Cd31 + progenitors. Our study was performed in Apoe −/− mice on high-cholesterol diet, which was suggested as a more valid model for characterizing the development of restenotic lesions after mechanical irritation, such as angioplasty. 59 However, as a limitation, it cannot be excluded that part of the observed effects might specifically be related to hypercholesterolemic conditions, requiring further investigation. Furthermore, although endothelial Cxcr4 deficiency did not reduce the luminal area in our injury model, it remains to be investigated whether such role in true restenosis could be revealed after more severe vascular injury with increased damage to the medial layer, as observed after angioplasty. Also, future studies are required to clarify the role of endothelial Cxcl12 in injury-induced neointimal hyperplasia and restenosis in more detail. 809 to C. Weber and A. Schober); the DFG International graduate school grant IRTG1508/1-TP6 (to B. Zhou, C. Weber, and J. Bernhagen); the German Heart Foundation/German Foundation of Heart Research (F/40/12 to H. Noels); and the START-Program of the Faculty of Medicine, RWTH Aachen (49/13 to H. Noels).
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